Johnson & Johnson yesterday was notified that the Food and Drug Administration now will require that the company add to the label of its COVID-19 vaccine a warning of a small, increased risk of Guillain-Barré syndrome, a rare but potentially serious neurological condition.

FDA notes that the window for the condition’s emergence is within 42 days of the vaccine’s administration. FDA said that because it has observed just 100 instances of Guillain-Barré among 12.8 million doses, with most people experiencing a full recovery, the risk is quite small compared to the risk of remaining unvaccinated against COVID-19. 

Related News Articles

Headline
The Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee today by a unanimous vote recommended that the FDA issue an…
Headline
The Centers for Disease Control and Prevention today revealed the comparative effectiveness of the three Food and Drug Administration-authorized COVID-19…
Headline
The Department of Health and Human Services’ Assistant Secretary for Preparedness and Response this week announced a major change in the distribution of…
Headline
The AHA has received a $1 million grant from the Centers for Disease Control and Prevention to continue for one year its efforts to encourage COVID-19…
Headline
A pair of peer-reviewed studies published in the New England Journal of Medicine are affirming the safety and effectiveness of Pfizer’s COVID-19 vaccine, first…
Headline
The Food and Drug Administration yesterday released an updated enforcement policy related to face masks, barrier face coverings, face shields,…